Can we use structural knowledge to design a protective vaccine against HIV-1?
- Creators
-
Bjorkman, Pamela J.
Abstract
HIV/AIDS remains one of the most important current threats to global public health. Since its identification in the early 1980s, at least 75 million people have been infected with HIV‐1, the virus that causes AIDS. Although anti‐retroviral drugs are effective at prolonging life after infection in the developed world, they are associated with significant side effects and are not in widespread use in the developing world. The best way to control the AIDS epidemic would be a vaccine that protects against infection by HIV‐1. Most vaccines work by inducing antibodies in serum or mucosa that block infection or prevent invasion of the bloodstream. Here I describe background related to my laboratory's attempts to develop an immunogen that would elicit protective antibodies against HIV‐1.
Additional Information
© 2019 Wiley. Issue Online: 01 January 2020; Version of Record online: 27 November 2019; Accepted manuscript online: 12 November 2019; Manuscript accepted: 08 November 2019; Manuscript received: 17 October 2019. Data Availability Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study. Funding Information: National Institutes of Health. Grant Number: P50 8 P50 AI150464‐13; National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Grant Number: HIVRAD P01 P01AI10014.Additional details
- Eprint ID
- 99882
- Resolver ID
- CaltechAUTHORS:20191118-073713001
- P50 8 P50 AI150464‐13
- NIH
- P01 P01AI10014
- NIH
- Created
-
2019-11-18Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field
- Caltech groups
- Division of Biology and Biological Engineering